Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. SHC
SHC logo

SHC Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
14.700
Open
14.600
VWAP
14.26
Vol
4.84M
Mkt Cap
4.00B
Low
14.030
Amount
69.08M
EV/EBITDA(TTM)
10.78
Total Shares
284.39M
EV
6.04B
EV/OCF(TTM)
21.02
P/S(TTM)
3.58
Sotera Health Company is a global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. The Company’s segments include Sterigenics, Nordion and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three technologies: gamma irradiation, ethylene oxide (EO) processing and E-beam irradiation. Nordion business is a global provider of Co-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. In addition, Nordion is a global provider of gamma irradiation systems. Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries.
Show More

Events Timeline

(ET)
2026-03-04
17:00:00
Sotera Health Launches Secondary Offering of 25 Million Shares
select
2026-02-24 (ET)
2026-02-24
07:30:00
Company Expects Net Revenues Between $1.233 Billion and $1.251 Billion
select
2026-02-24
07:30:00
Sotera Health Appoints New General Counsel
select
2026-02-24
07:20:00
Company Reports Q4 Revenue of $303M, Beating Expectations
select
2026-02-24
07:20:00
Company Reports Q4 Revenue of $303M, Beating Expectations
select
2026-02-05 (ET)
2026-02-05
07:40:00
Sotera Health Appoints Richard Kyle as Independent Director
select

News

NASDAQ.COM
2.0
03-05NASDAQ.COM
Analysis of SHC Stock's 52-Week Highs and Lows
  • Price Range Analysis: SHC's stock has a 52-week low of $9.53 and a high of $19.85, with the last trade at $15.28, indicating a stable price within this range that may attract investor interest.
  • Market Trend Observation: The current stock price is approximately 77% of the 52-week high, suggesting a relatively strong market confidence in SHC, which could influence investor buying decisions.
  • Technical Indicator Analysis: SHC's trading price is below its 200-day moving average, potentially indicating short-term downside risks, prompting investors to carefully assess their holding strategies.
  • Investor Sentiment: While the current stock price shows some stability within the 52-week range, there remains a divergence in market views regarding its future performance, necessitating investor attention to subsequent market dynamics for informed decision-making.
seekingalpha
8.5
03-04seekingalpha
Sotera Health Launches 25 Million Share Secondary Offering
  • Secondary Offering Size: Sotera Health Company announced that certain affiliates of Warburg Pincus and GTCR are offering 25 million shares of common stock, indicating ongoing market interest in its shares.
  • Company Not Selling Shares: The company stated it will not sell any shares and will not receive any proceeds, but will cover the offering expenses, reflecting its commitment to shareholder interests.
  • Diverse Transaction Methods: The shares may be sold on Nasdaq, in the over-the-counter market, or through negotiated transactions at market or negotiated prices, providing flexible trading options to attract investors.
  • Registration Statement Effective: The registration statement related to these shares was filed with the U.S. Securities and Exchange Commission on February 7, 2024, and became effective automatically, ensuring compliance and paving the way for the offering.
NASDAQ.COM
6.5
03-02NASDAQ.COM
Ananym Capital Management Reduces Stake in Sotera Health
  • Share Reduction Details: Ananym Capital Management sold 217,684 shares of Sotera Health in Q4 2026 for an estimated $3.60 million, indicating ongoing confidence in the company despite the modest reduction in stake.
  • Quarter-End Position Changes: At the end of the quarter, Ananym's total position stood at 1,192,833 shares valued at $21.04 million, reflecting a decrease of $1.15 million due to trading activities and share price fluctuations.
  • Company Performance: Sotera Health achieved its 20th consecutive year of revenue growth in 2025, with net revenues nearing $1.16 billion and adjusted EBITDA rising 8% to $594 million, underscoring its critical role in the healthcare and pharmaceutical sectors.
  • Future Outlook: Management projects a revenue increase of 5% to 6.5% for 2026, alongside adjusted EBITDA growth of 5.5% to 7%, highlighting the company's strategic advantages in maintaining steady demand and reliability.
Fool
5.0
03-02Fool
Ananym Capital Management Reduces Stake in Sotera Health
  • Share Reduction Details: On February 17, 2026, Ananym Capital Management disclosed the sale of 217,684 shares of Sotera Health, valued at approximately $3.60 million, indicating ongoing confidence in the company despite a reduced stake of 8.65%.
  • Strong Financial Performance: Sotera Health achieved nearly 6% revenue growth in 2025, reaching $1.16 billion, with net income nearly doubling to $78 million, highlighting its robust demand and market position in the medical device and pharmaceutical sectors.
  • Positive Future Outlook: Management projects a revenue increase of 5% to 6.5% for 2026, alongside adjusted EBITDA growth of 5.5% to 7.0%, indicating the company's potential for sustained growth in a stable market environment.
  • Investor Confidence: Although the $3.6 million trade represents a reduction, Sotera Health still constitutes nearly 9% of Ananym's portfolio, reflecting confidence in its business model and a strategic approach to risk management.
seekingalpha
9.5
02-24seekingalpha
Sotera Health Company Q4 2025 Earnings Call Insights
  • Consistent Performance: Sotera Health achieved a 5.7% revenue increase in 2025, reaching $1.164 billion, marking 20 consecutive years of growth, which underscores the company's stability and potential in the market.
  • Cash Flow Strength: Adjusted free cash flow exceeded $200 million, reflecting successful operational efficiency and cost control, further enhancing the company's financial health and investment capacity.
  • Optimistic Outlook: Total revenue for 2026 is projected to reach between $1.233 billion and $1.251 billion, with a growth rate of 5% to 6.5%, indicating the company's confidence in future market demand and ongoing growth strategies.
  • Management Changes: The company announced executive changes, with Alex Dimitrief transitioning to an outside adviser and Erika Ostrowski promoted to Senior Vice President and General Counsel, reflecting strategic adjustments in leadership.
seekingalpha
9.5
02-24seekingalpha
Sotera Health Q4 Earnings Beat Expectations with Strong Outlook
  • Earnings Beat: Sotera Health reported a Q4 non-GAAP EPS of $0.26, exceeding expectations by $0.02, indicating the company's stable profitability and growth potential amidst market fluctuations.
  • Revenue Miss: The Q4 revenue of $259.04 million, while up 8.5% year-over-year, fell short of expectations by $41.63 million, highlighting challenges from increased competition and demand variability in the market.
  • Positive 2026 Outlook: The company forecasts net revenues between $1.233 billion and $1.251 billion for 2026, surpassing consensus estimates and suggesting a stable growth trajectory of 5% to 6.5% despite foreign currency impacts.
  • Capital Expenditure Plans: Sotera Health plans to invest between $175 million and $225 million in capital expenditures over the next year, aimed at enhancing production capacity and technological investments to support its long-term growth strategy.
Wall Street analysts forecast SHC stock price to rise
9 Analyst Rating
Wall Street analysts forecast SHC stock price to rise
7 Buy
2 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
16.00
Averages
20.42
High
24.00
Current: 0.000
sliders
Low
16.00
Averages
20.42
High
24.00
Citi
Patrick Donnelly
Buy
maintain
$21 -> $23
AI Analysis
2026-02-25
Reason
Citi
Patrick Donnelly
Price Target
$21 -> $23
AI Analysis
2026-02-25
maintain
Buy
Reason
Citi analyst Patrick Donnelly raised the firm's price target on Sotera Health to $23 from $21 and keeps a Buy rating on the shares.
Citi
Buy
maintain
$21 -> $23
2026-02-24
Reason
Citi
Price Target
$21 -> $23
2026-02-24
maintain
Buy
Reason
Citi raised the firm's price target on Sotera Health to $23 from $21 and keeps a Buy rating on the shares. The company established FY26 guidance calling for total revenue growth of 5%-6.5%, which translates to $1.233B-$1.251B, and an adjusted EPS midpoint of 97c, slightly above expectations, the analyst tells investors. Management took "a prudent approach" in the guidance, the analyst added.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for SHC
Unlock Now

Valuation Metrics

The current forward P/E ratio for Sotera Health Co (SHC.O) is 19.16, compared to its 5-year average forward P/E of 19.21. For a more detailed relative valuation and DCF analysis to assess Sotera Health Co's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
19.21
Current PE
19.16
Overvalued PE
24.01
Undervalued PE
14.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
12.11
Current EV/EBITDA
11.41
Overvalued EV/EBITDA
15.16
Undervalued EV/EBITDA
9.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
4.44
Current PS
4.18
Overvalued PS
6.03
Undervalued PS
2.84

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

best medical 3 stocks to buy under $20
Intellectia · 22 candidates
Market Cap: >= 500.00MPrice: <= $20.00Beta: LowRiskWeekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
TAK logo
TAK
Takeda Pharmaceutical Co Ltd
51.17B
HLN logo
HLN
Haleon PLC
45.60B
KVUE logo
KVUE
Kenvue Inc
33.30B
VTRS logo
VTRS
Viatris Inc
15.03B
RDY logo
RDY
Dr Reddy's Laboratories Ltd
11.06B
BAX logo
BAX
Baxter International Inc
10.13B

Whales Holding SHC

T
Two Seas Capital LP
Holding
SHC
+3.99%
3M Return
G
Greenlight Capital, Inc.
Holding
SHC
+1.58%
3M Return
D
Darsana Capital Partners LP
Holding
SHC
-0.96%
3M Return
S
Sachem Head Capital Management LP
Holding
SHC
-2.78%
3M Return
G
GTCR LLC
Holding
SHC
-5.78%
3M Return
S
Sessa Capital IM, L.P.
Holding
SHC
-10.07%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Sotera Health Co (SHC) stock price today?

The current price of SHC is 14.06 USD — it has decreased -3.5

What is Sotera Health Co (SHC)'s business?

Sotera Health Company is a global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. The Company’s segments include Sterigenics, Nordion and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three technologies: gamma irradiation, ethylene oxide (EO) processing and E-beam irradiation. Nordion business is a global provider of Co-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. In addition, Nordion is a global provider of gamma irradiation systems. Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries.

What is the price predicton of SHC Stock?

Wall Street analysts forecast SHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SHC is20.42 USD with a low forecast of 16.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Sotera Health Co (SHC)'s revenue for the last quarter?

Sotera Health Co revenue for the last quarter amounts to 303.44M USD, increased 4.56

What is Sotera Health Co (SHC)'s earnings per share (EPS) for the last quarter?

Sotera Health Co. EPS for the last quarter amounts to 0.12 USD, increased 200.00

How many employees does Sotera Health Co (SHC). have?

Sotera Health Co (SHC) has 3000 emplpoyees as of March 11 2026.

What is Sotera Health Co (SHC) market cap?

Today SHC has the market capitalization of 4.00B USD.